Safety and Efficacy of the AbsnowTM II Absorbable Atrial Septal Defect Closure System for Atrial Septal Defect Closure Therapy

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 236 participants.

Also called NCT07529028

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 236 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07529028
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07529028. Randomized; no masking; primary purpose treatment. Start 2026-04 (anticipated); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of the AbsnowTM II Absorbable Atrial Septal Defect Closure System for Atrial Septal Defect Closure Therapy
Condition
Atrial Septal Defect
Intervention (Device)
Absnow II Absorbable Atrial Septal Defect Occluder System
Intervention (Device)
Cera Atrial Septal Defect Occluder
Lead sponsor
Lifetech Scientific (Shenzhen) Co., Ltd. (class: industry)
Collaborator
Chinese Academy of Medical Sciences, Fuwai Hospital (class: other)
Collaborator
Fuwai Yunnan Cardiovascular Hospital (class: other)
Collaborator
Guangdong Provincial People's Hospital (class: other)
Collaborator
Chinese PLA General Hospital (class: other)
Collaborator
Lanzhou University Second Hospital (class: other)
Collaborator
The Children's Hospital of Zhejiang University School of Medicine (class: other)
Collaborator
Beijing Anzhen Hospital (class: other)

Record details

Record id
cardio:ct-nct07529028
Content hash
2230090747d39c67be4b0df5c77c301feb5aaf9d143e2129501fb836b8423fac